What is HC Wainwright’s Forecast for ARWR Q3 Earnings?

Posted by Stanley Muller on May 14th, 2026

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) – Stock analysts at HC Wainwright decreased their Q3 2026 earnings estimates for Arrowhead Pharmaceuticals in a report released on Tuesday, May 12th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will earn ($1.03) per share for the quarter, down from their prior estimate of ($1.02). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.98) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($2.68) EPS, Q1 2027 earnings at ($1.04) EPS, Q2 2027 earnings at ($1.25) EPS, Q3 2027 earnings at ($1.26) EPS and FY2027 earnings at ($3.37) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. The company had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm’s revenue for the quarter was down 86.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.75 earnings per share.

Other equities analysts have also recently issued reports about the stock. Royal Bank Of Canada upped their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. Sanford C. Bernstein upped their price objective on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday. B. Riley Financial upped their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a report on Friday, May 1st. They set an “overweight” rating and a $88.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $87.80.

View Our Latest Analysis on ARWR

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $77.88 on Thursday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The company has a fifty day moving average of $65.40 and a two-hundred day moving average of $61.45. The stock has a market capitalization of $10.97 billion, a PE ratio of -36.22 and a beta of 1.28. Arrowhead Pharmaceuticals has a fifty-two week low of $14.30 and a fifty-two week high of $80.67.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently modified their holdings of ARWR. Cetera Investment Advisers lifted its position in Arrowhead Pharmaceuticals by 40.7% in the first quarter. Cetera Investment Advisers now owns 9,424 shares of the biotechnology company’s stock valued at $591,000 after buying an additional 2,727 shares during the last quarter. WCM Investment Management LLC lifted its position in Arrowhead Pharmaceuticals by 23.5% in the first quarter. WCM Investment Management LLC now owns 171,575 shares of the biotechnology company’s stock valued at $9,891,000 after buying an additional 32,670 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Arrowhead Pharmaceuticals by 312.8% during the first quarter. Dimensional Fund Advisors LP now owns 608,531 shares of the biotechnology company’s stock worth $38,150,000 after purchasing an additional 461,119 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals by 407.1% during the first quarter. Parallel Advisors LLC now owns 1,004 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 806 shares in the last quarter. Finally, SEB Asset Management AB acquired a new stake in shares of Arrowhead Pharmaceuticals during the first quarter worth about $9,919,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Daniel Joseph Apel sold 13,095 shares of the company’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the sale, the chief financial officer owned 162,905 shares of the company’s stock, valued at $11,623,271.75. This represents a 7.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. Following the sale, the insider directly owned 226,958 shares of the company’s stock, valued at $17,021,850. The trade was a 4.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 33,095 shares of company stock valued at $2,326,228 in the last ninety days. Insiders own 3.60% of the company’s stock.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

Positive Sentiment: HC Wainwright reiterated a Buy rating and $100 price target on Arrowhead Pharmaceuticals, while raising estimates for FY2026 and Q4 2026 and lifting its Q4 2027 profit forecast. MarketBeat Arrowhead Pharmaceuticals report
Positive Sentiment: Sanford C. Bernstein raised its price target from $35 to $46, signaling improved longer-term confidence in Arrowhead Pharmaceuticals even though the rating remains market perform. Benzinga report
Positive Sentiment: Arrowhead’s recent strategic momentum, including its global license and collaboration agreement with Sarepta Therapeutics, continues to support investor optimism around the pipeline and partnership value. Business Wire article
Neutral Sentiment: HC Wainwright made small, mixed EPS revisions across several quarters, with some periods nudged lower and others higher; the changes were modest and do not materially alter the overall bullish stance. MarketBeat Arrowhead Pharmaceuticals report
Negative Sentiment: Bernstein’s new target of $46 is still well below Arrowhead’s recent trading level, implying meaningful downside if the stock rerates back toward that valuation. Benzinga report

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.